Proteinuria
Drug research and approvals for proteinuria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 49 studies of proteinuria are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 9 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 49
- Trials authorized in Canada: 0
- FDA orphan approvals: 9
- EU medicines: 0
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyNCT07902817 · Phase 3 · Jade Biosciences, Inc. · starts Dec 1, 2026
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyNCT07850752 · Phase 3 · Novartis Pharmaceuticals · starts Nov 11, 2026
- A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgANNCT07773727 · Phase 2 · argenx · starts Nov 5, 2026
- A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic…NCT07561957 · Not applicable · St. James's Hospital, Ireland · starts Jan 14, 2026
- A Study of JADE101 in Participants With Immunoglobulin A NephropathyNCT07541287 · Phase 2 · Jade Biosciences, Inc. · starts May 19, 2026
- Characterization of Renal Microvascular Alterations in Patients With Active Urinary Sediment and/or Proteinuria Using…NCT07469059 · Not reported · University of Erlangen-Nürnberg Medical School · starts Sep 18, 2025
- Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe ProteinuriaNCT07431931 · Not applicable · Geisinger Clinic · starts Nov 1, 2026
- A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 GlomerulopathyNCT07416162 · Not reported · Novartis Pharmaceuticals · starts Jun 15, 2026
- Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney…NCT07405216 · Phase 4 · Centenario Hospital Miguel Hidalgo · starts Apr 23, 2026
Approved 1
- LosartanType-1 angiotensin II receptor antagonist
Phase 3 9
- Olmesartan medoxomilType-1 angiotensin II receptor antagonist
- Curcumin
- Candesartan cilexetilType-1 angiotensin II receptor antagonist
- EnalaprilAngiotensin-converting enzyme inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- DextromethorphanSigma opioid receptor agonist
- ParicalcitolVitamin D receptor agonist
- AmlodipineVoltage-gated L-type calcium channel blocker
- Silybin a
Phase 2 4
- BelataceptT-lymphocyte activation antigen CD86 inhibitor
- SitaxentanEndothelin receptor, ET-A/ET-B antagonist
- NifedipineVoltage-gated L-type calcium channel blocker
- Pirfenidone
Phase 1 or earlier 1
How its trials ended
195 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 47 whose ending is known, 38% met their primary endpoint, 6% missed it and 55% stopped early.
- Completed, result not reported8443%
- Status unknown4021%
- Ongoing2412%
- Met its primary endpoint189%
- Stopped: other or unclear189%
- Stopped: enrollment or feasibility84%
- Missed its primary endpoint32%
| Nov 13, 2026 | GazyvaTreatment of adult patients with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria | Genentech, Inc., A Member of the Roche Group | Approved |
| Aug 20, 2026 | EmpaveliTreatment of adult and pediatric patients aged 12 years and older with primary immune-complex membranoproliferative glomerulonephritis… | Apellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc. | Approved |
| Aug 20, 2026 | EmpaveliTreatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuria and the loss of… | Apellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc. | Approved |
| Apr 13, 2026 | FilspariTo reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without… | Travere Therapeutics, Inc. | Approved |
| Jul 28, 2025 | EmpaveliTreatment of adult and pediatric patients aged 12 years and older with primary immune-complex membranoproliferative glomerulonephritis… | Apellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc. | Approved |
| Jul 28, 2025 | EmpaveliTreatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuria | Apellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc. | Approved |
| Mar 20, 2025 | FabhaltaTreatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria | Novartis Pharmaceuticals Corporation | Approved |
| Feb 17, 2023 | FilspariTo reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine… | Travere Therapeutics, Inc. | Approved |
| Dec 15, 2021 | TarpeyoTo reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine… | Calliditas Therapeutics AB | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA